J. P. Jordaan

Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva

Kathy S. Albain, S. Nag, G. Calderillo-Ruiz et al. · Journal of Clinical Oncology · 2004 · 155 citations

Overall Surviva, Breast Oncology, Cancer Management +16

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani et al. · The Lancet · 2023 · 151 citations · Full text

Hypertension, Renal Function, Renal Disease +10

A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen

Paul Ruff, Daniel Vorobiof, J. P. Jordaan et al. · Cancer Chemotherapy and Pharmacology · 2009 · 82 citations

Breast Oncology, Oncology, Health Sciences +10

Oral granisetron alone and in combination with dexamethasone: A double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis

Jean‐François Héron, L. Goedhals, J. P. Jordaan et al. · Annals of Oncology · 1994 · 75 citations · Full text

Oncology, Cisplatin-induced Emesis, Medicine +6

Fadrozole versus Megestrol Acetate: A Double-Blind Randomised Trial in Advanced Breast Cancer

W. R. Bezwoda, A. Gudgeon, Geoffrey Falkson et al. · Oncology · 1998 · 15 citations

Advanced Breast Cancer, Megestrol Acetate, Oncology +14